The latest shared research on Roche
Webinar: What Is The Outlook for the Pharma Top 10
Reserve a free place at our webinar to explore the challenges and opportunities facing the top 10 pharma companies: In response to the popularity of our recent focus on leading pharma companies, we are pleased to present this exclusive roundtable discussion, hosted by a panel of experts from the industry's leading research providers. This webinar presentation, only available to members of the PharmaShare community, will explore the latest trends within the evolving company landscape, including: Recent company performances that have shaped the competitive landscape and the strategies that have proven to be most effective in driving growth. The outlook for leading companies through ...
Dalcetrapib and Anacetrapib: A Tale of Two CETPs
Gail Parziale Senior Director, Cardiovascular and Metabolic/Endocrinology Citeline Background on CETP inhibition and the torcetrapib failure Cholesteryl ester transfer protein (CETP) inhibition represents a novel treatment approach for patients with dyslipidemia. This class of drugs works by raising levels of high-density lipoprotein cholesterol (HDL-c), the so-called good cholesterol known to have antiatherogenic and cardioprotective effects. Because current treatment options for patients with decreased HDL are limited, this new therapeutic approach has generated much excitement in the medical community. Pfizer’s torcetrapib had been the front runner in this new therapeutic class when its development was unexpectedly halted in December 2006 following safety concerns that arose during ...
Roche Hands Phase II Diabetes Candidate Back to Chugai Amid ‘Reprioritisation’
Sukaina Virji sukaina.virji@informa.com Chugai Pharmaceutical's parent company Roche is to return to the Japanese firm the development and marketing rights for CSG452, a SGLT2 inhibitor, discovered by Chugai and in development for the treatment of type II diabetes. Roche told Scrip it was "purely a prioritisation-related decision" and not related to any clinical issues. The pharma giant insisted it still had a "strong metabolic pipeline with around ten projects in Phase I and beyond". In a statement, Chugai said: "Roche has recently reviewed the priority of its development pipeline, and has decided to return…this compound to Chugai." The companies signed a licence agreement in ...
Conference Insight: American Diabetes Association 71st Scientific Sessions 2011
Datamonitor’s highlights of key drugs and classes OVERVIEW Datamonitor has identified the following key highlights in antidiabetic drugs from the 71st Scientific Sessions of the American Diabetes Association (ADA) held in San Diego, California over June 24–28, 2011: The GLP-1 agonist class has a lot of development interest. First-to-market GLP-1 agonist exenatide is approaching market in the once-weekly formulation Bydureon (Amylin/Eli Lilly), for which more long-term trial data were released showing effects persisting for up to 3 years of treatment. A once-monthly formulation revealed comparable efficacy and safety to the once-weekly drug in a Phase II dose-ranging trial, while Intarcia’s subcutaneous implant ITCA 650 ...
Evotec and Roche Team Up to Develop Oncology Biomarkers
Gemma Sharman gemma.sharman@informa.com Evotec and Roche will be collaborating to develop novel biomarkers for Roche's oncology drugs using Evotec's PhosphoScout platform, in what will be the first commercial application of the platform since Evotec inherited it from its acquisition of Kinaxo earlier this year (scripintelligence.com, 15 February). Under the initial three-year term, Evotec will deliver novel protein-activity based biomarkers using the PhosphoScout platform, while Roche will be responsible for conducting clinical trials as well as assessing the development of companion diagnostics for patient stratification. "Kinaxo has already signed similar PhosphoScout deals with Takeda in March 2011 and Daiichi Sankyo in October 2010, but ...
Latest Roche Research: Clinical Outcome with Bevacizumab in Patients with Recurrent High-Grade Glioma Treated Outside Clinical Trials
Abstract from: Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials, Silvia Hofer et al., Acta Oncologica Jun 2011, Vol. 50, No. 5, Pages 630-635: 630-635. Background: Patients with recurrent high-grade glioma (HGG) have a poor prognosis and there is no defined standard of care. High levels of vascular endothelial growth factor (VEGF) expressed in HGG make the anti-VEGF monoclonal antibody bevacizumab (BEV) of particular interest. Patients and methods: In an ongoing registry data were collected from patients who have received BEV for the treatment of recurrent HGG. The primary objective was the identification of any clinical benefit ...
Latest Roche Research: Maintenance Rituximab Following Induction Chemo-Immunotherapy for Mantle Cell Lymphoma
Abstract from: Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network, Vaishalee P. Kenkre et al., Leukemia & Lymphoma : 1-6. Posted online on 17 May 2011. Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3–5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) with maintenance rituximab. The complete response rate was 64%, and median progression-free ...
Roche to Begin Phase III of Personalised MetMab Treatment in NSCLC
Pial Ganguli Roche is set to begin a Phase III trial later this year of its personalised medicine, MetMab, after final results from a Phase II lung cancer trial confirmed preliminary findings that the product, used in combination with Tarceva (Roche’s erlotinib), doubles survival time without worsening disease compared with Tarceva alone. MetMab, which the company has previously highlighted as a “possible long-term growth driver”, is a humanised monovalent monoclonal antibody designed to block Met signalling in cancer cells. The Met protein (or receptor) is associated with a poor outcome in many cancers. The product is also being evaluated in combination ...
